Pharma News

Researchers have uncovered a surprising new mechanism behind memory loss in Alzheimer’s disease, identifying dopamine deficiency as a major contributor to cognitive decline. The discovery could open the door to new treatment approaches aimed at restoring memory in patients suffering from the disease.

The study was led by scientists at Tohoku University in collaboration with researchers from the University of California, Irvine. Their findings were published in the journal Nature Neuroscience on April 23, 2026.

A major breakthrough in diabetes research could one day free patients with type 1 diabetes from lifelong insulin injections. Researchers from Université de Genève and Geneva University Hospitals have developed an innovative protective hydrogel capable of supporting insulin-producing cells after transplantation, successfully restoring blood sugar control in diabetic mice.

Indian drug maker Alembic Pharmaceuticals has reported a strong financial performance for the fourth quarter of FY26, driven by steady growth in domestic formulations, robust US business expansion, and its strategic entry into the branded pharmaceuticals segment in the United States.

In a significant regulatory achievement, Alembic Pharmaceuticals has successfully cleared a Good Manufacturing Practices (GMP) inspection conducted by Brazil’s health regulatory authority, ANVISA, for its API-III manufacturing facility located at Karakhadi, Gujarat.

According to the company’s regulatory filing submitted to stock exchanges on May 15, 2026, the inspection was carried out from May 11 to May 15, 2026, and concluded without any observations.

India-based pharmaceutical giant Dr. Reddy's Laboratories has announced the launch of its generic Semaglutide Injection in Canada, becoming one of the first companies to introduce the product in the Canadian market following approval from Health Canada.

The World Health Organization has officially declared the ongoing Ebola outbreak in the Democratic Republic of the Congo and Uganda a “Public Health Emergency of International Concern” (PHEIC), raising global alarm over the rapid spread of the deadly virus across Central Africa.

The U.S. Department of Commerce has launched a new application process that could allow pharmaceutical companies to significantly reduce looming Section 232 tariffs if they commit to moving drug manufacturing operations to the United States.

Genentech has announced that the U.S. Food and Drug Administration (FDA) has approved Tecentriq and Tecentriq Hybreza for the adjuvant treatment of adults with muscle-invasive bladder cancer (MIBC) who show circulating tumor DNA molecular residual disease (ctDNA MRD) after bladder removal surgery. The approval marks the first FDA-cleared ctDNA-guided therapy approach for this aggressive cancer type.